Eli Lilly's Revenue Surges Amid Declining Coverage for GLP-1 Weight-Loss Drugs
Eli Lilly has recently announced a remarkable 47% increase in its second-quarter revenue, totaling $22.97 billion, even as employer insurance coverage for GLP-1 weight-loss drugs has seen a notable decline from 72% in 2025 to 60% in 2026. This juxtaposition of rising revenue alongside decreasing coverage prompts an examination of the current landscape of weight-loss treatments and their accessibility.
The decline in coverage could signal a shift in how employers view the cost-effectiveness of GLP-1 medications, which are designed to mimic a gut hormone that regulates appetite and blood sugar levels. Notably, Eli Lilly's Zepbound and Mounjaro have emerged as key players in this market, with Zepbound generating $4.93 billion and Mounjaro contributing $9.94 billion to the revenue.
Despite the drop in coverage, the volume of prescriptions for these medications continues to rise, suggesting that while insurance reimbursement may be tightening, patient demand remains strong. This is evidenced by a 60% increase in prescription volumes, which has more than compensated for a 13% decrease in realized prices. Such dynamics indicate that while the financial landscape for GLP-1 drugs is changing, the appetite for these treatments persists.
However, the implications of reduced insurance coverage are significant. As employers begin to limit their offerings, patients may face higher out-of-pocket costs, potentially leading to a shift towards cash-pay options. Approximately 14% of surveyed employers have indicated they have either dropped or plan to drop these medications by 2027, a trend that could have serious ramifications for accessibility and affordability.
The financial burden of GLP-1 medications is already a concern, as pharmacy benefits now account for about one-quarter of employer healthcare spending. Many employers are yet to see substantial savings from the anticipated reductions in obesity-related health complications, which complicates their willingness to continue coverage. This mismatch between immediate budgetary constraints and long-term health benefits reflects a broader challenge in the healthcare system, where annual budgeting cycles often clash with the multi-year timelines required to realize the benefits of such treatments.
As Eli Lilly adapts to these changes, it has begun to explore alternative avenues for patient access. The company’s Lilly Employer Connect program offers Zepbound at a competitive price of $449 per month, undercutting the higher retail prices that employers have been hesitant to embrace. Furthermore, initiatives like the Medicare GLP-1 Bridge Program, which allows for a $50 monthly out-of-pocket cost, are expanding access even as commercial coverage narrows.
In conclusion, while Eli Lilly's financial performance continues to thrive, the landscape for GLP-1 weight-loss drugs is shifting. The decline in insurance coverage raises important questions about the future of these medications and their accessibility to patients, highlighting the need for ongoing dialogue about healthcare affordability and patient support in the realm of weight management.




